Investing in Pharmacyclics
We are a fully integrated biopharmaceutical company developing and commercializing a robust pipeline of innovative drugs for the treatment of cancers and immune-mediated diseases. We uphold the idea that therapies should help without causing more harm. We believe in truly serving patients, their families, and caregivers.
Our first patient was treated in a clinical trial in February 2009 and, in November 2013, we achieved our first regulatory approval. Including our clinical trials, to date we have treated thousands of patients impacted by life-threatening diseases. Our studies are being conducted in 35 countries, and we collaborate with more than 800 investigators in medical institutions.
Our visionary leadership, scientific expertise, commercial experience, operational integrity, and organizational tenacity have been essential in helping us fulfill our promise of providing targeted and patient-friendly therapies.